Servier, a global pharmaceutical group governed by a foundation, has strengthened its India strategy by launching GATINN, a dedicated platform focused on the development, manufacturing, and export of Single Pill Combinations (SPCs) for cardiometabolic and venous diseases. Through this initiative, Servier aims to simplify complex treatment regimens, improve patient adherence, and deliver better long-term health outcomes. At the same time, the platform supports the company’s broader Servier 2030 ambition to accelerate innovation and provide more patient-centric therapies for chronic conditions.
Improving Treatment Adherence Through Simplified Therapies
Single Pill Combinations combine multiple medicines into one tablet, reducing pill burden and helping patients follow prescribed treatments more consistently. By prioritising SPC development, Servier directly addresses one of the most persistent challenges in chronic disease management — poor adherence. As a result, the company expects improved clinical outcomes and more effective disease control for patients worldwide.
What GATINN Stands For
Dr Kshitij Panse, Chief Operating Officer – GATINN, said, “GATINN embodies Servier’s strategy to address critical patient unmet needs by accelerating patient-centric innovation. ‘GATI’ signifies speed, reflecting our focus on rapidly delivering solutions, while ‘INN’ represents innovation in India. By combining a dedicated local team, carefully selected partners, and Servier’s global R&D, manufacturing, and quality expertise, we are building a platform to execute high-quality SPCs that meet global standards and help improve adherence and outcomes for patients worldwide.” In essence, the platform blends local execution strength with global scientific and quality capabilities, enabling faster development and market access.
Investment and Operational Structure
To power the initiative, Servier plans to invest approximately €15 million in 2026. The company will collaborate closely with Indian partners to accelerate production and delivery.
Importantly, the GATINN platform integrates:
*Product development
*Manufacturing
*Supply chain coordination
Quality oversight
All these functions will operate through a central coordination hub located in India, ensuring efficient end-to-end execution. While manufacturing will be carried out through selected Indian CDMO partners, Servier will continue sourcing active pharmaceutical ingredients (APIs) from its own production facilities, where it remains the originator. This hybrid model ensures both cost efficiency and stringent quality standards.
A Global-Local Collaboration Model
Servier’s approach strategically combines:
*Research capabilities from France
*Development and manufacturing expertise in India
Together, this structure supports supply to high-growth markets across Asia, Latin America, Africa, and the Middle East. Charlotte Marmousez, Executive Vice President, Corporate Strategy & Transformation, noted, “The decision to establish GATINN in India aligns with Servier’s global strategy to advance patient-centered innovation by developing top-quality SPCs to improve patient adherence. This is Servier’s first such platform, which will coordinate global research and manufacturing teams from our headquarters in France.”
Product Pipeline and Launch Timeline
Servier has already initiated projects under the GATINN platform. The company expects:
*First international launch in Q2 2027
*Around five SPC products in development by the end of 2026
*Approximately one additional SPC added annually through 2030
The steady pipeline expansion will strengthen Servier’s long-term presence in cardiometabolic and vascular care while positioning India as a key export hub.
Strengthening India’s Role in Global Pharma Supply
With the launch of GATINN, Servier reinforces India’s growing importance as a strategic development and manufacturing base for global pharmaceutical supply. As reported by expresspharma.in, by leveraging India’s strong CDMO ecosystem and combining it with Servier’s global expertise, the company aims to deliver high-quality, affordable, and patient-focused therapies to markets worldwide. Ultimately, the platform represents a significant step toward faster innovation, better access, and improved outcomes in chronic disease treatment.
